NASDAQ:ZVRA Zevra Therapeutics (ZVRA) Stock Price, News & Analysis $12.65 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$12.76 +0.11 (+0.87%) As of 06/12/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Zevra Therapeutics Stock (NASDAQ:ZVRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zevra Therapeutics alerts:Sign Up Key Stats Today's Range$12.63▼$13.7450-Day Range$9.40▼$13.6652-Week Range$7.16▼$14.27Volume1.72 million shsAverage Volume2.19 million shsMarket Capitalization$747.87 millionP/E Ratio6.36Dividend YieldN/APrice Target$29.29Consensus RatingModerate Buy Company Overview Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. Read More Zevra Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreZVRA MarketRank™: Zevra Therapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 75th out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingZevra Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialZevra Therapeutics has a consensus price target of $29.29, representing about 131.5% upside from its current price of $12.65.Amount of Analyst CoverageZevra Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Zevra Therapeutics' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth69.64% Earnings GrowthEarnings for Zevra Therapeutics are expected to grow by 69.64% in the coming year, from $0.56 to $0.95 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zevra Therapeutics is 6.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.00.Price to Earnings Ratio vs. SectorThe P/E ratio of Zevra Therapeutics is 6.36, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.22.Price to Book Value per Share RatioZevra Therapeutics has a P/B Ratio of 4.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zevra Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.34% of the float of Zevra Therapeutics has been sold short.Short Interest Ratio / Days to CoverZevra Therapeutics has a short interest ratio ("days to cover") of 2.74, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zevra Therapeutics has recently increased by 34.24%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZevra Therapeutics does not currently pay a dividend.Dividend GrowthZevra Therapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.15 News SentimentZevra Therapeutics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Zevra Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 13 people have searched for ZVRA on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zevra Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.40% of the stock of Zevra Therapeutics is held by insiders.Percentage Held by Institutions35.03% of the stock of Zevra Therapeutics is held by institutions.Read more about Zevra Therapeutics' insider trading history. Receive ZVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZVRA Stock News HeadlinesZevra Therapeutics: Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned TransitionJune 11, 2026 | finanznachrichten.deZevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned TransitionJune 11, 2026 | markets.businessinsider.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned TransitionJune 11, 2026 | globenewswire.comZevra Therapeutics Target of Unusually High Options Trading (NASDAQ:ZVRA)June 10, 2026 | americanbankingnews.comIs Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat?June 9, 2026 | finance.yahoo.comZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?June 9, 2026 | finance.yahoo.comZevra Therapeutics extends MIPLYFFA exclusivity to 2041June 8, 2026 | finance.yahoo.comSee More Headlines ZVRA Stock Analysis - Frequently Asked Questions How have ZVRA shares performed this year? Zevra Therapeutics' stock was trading at $8.96 at the start of the year. Since then, ZVRA shares have increased by 41.2% and is now trading at $12.65. How were Zevra Therapeutics' earnings last quarter? Zevra Therapeutics, Inc. (NASDAQ:ZVRA) announced its earnings results on Wednesday, May, 6th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.12. The firm earned $36.22 million during the quarter, compared to analysts' expectations of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a trailing twelve-month return on equity of 51.49%. Read the conference call transcript. When did Zevra Therapeutics IPO? Zevra Therapeutics (ZVRA) raised $66 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 5,090,909 shares at $12.00-$14.00 per share. Who are Zevra Therapeutics' major shareholders? Top institutional shareholders of Zevra Therapeutics include AIGH Capital Management LLC (2.03%), Dimensional Fund Advisors LP (0.94%), Janney Montgomery Scott LLC (0.40%) and Bank of New York Mellon Corp (0.29%). Insiders that own company stock include Neil F Mcfarlane, Joshua Schafer, R Laduane Clifton, John B Bode, Timothy J Sangiovanni, Thomas Anderson, Adrian W Quartel, Tamara A Favorito and Corey Michael Watton. View institutional ownership trends. How do I buy shares of Zevra Therapeutics? Shares of ZVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zevra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zevra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Tesla (TSLA). Company Calendar Last Earnings5/06/2026Today6/14/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 ZVRA's financial health is in the Green zone, according to TradeSmith. ZVRA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZVRA CIK1434647 Webwww.kempharm.com Phone(321) 939-3416Fax319-665-2577Employees20Year Founded2006Price Target and Rating Average Price Target for Zevra Therapeutics$29.29 High Price Target$35.00 Low Price Target$25.00 Potential Upside/Downside+131.5%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)$1.99 Trailing P/E Ratio6.36 Forward P/E Ratio22.59 P/E GrowthN/ANet Income$83.23 million Net Margins101.58% Pretax Margin109.08% Return on Equity51.49% Return on Assets28.86% Debt Debt-to-Equity RatioN/A Current Ratio4.89 Quick Ratio4.84 Sales & Book Value Annual Sales$106.47 million Price / Sales7.02 Cash Flow$0.95 per share Price / Cash Flow13.37 Book Value$2.75 per share Price / Book4.60Miscellaneous Outstanding Shares59,120,000Free Float57,696,000Market Cap$747.87 million OptionableOptionable Beta0.91 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ZVRA) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
